Objective. The response rate to many therapies for RA is lower in women. The aim of this study was to analyse the influence of gender on the response to rituximab (RTX) in patients with RA.
Introduction
It is clearly established that RA affects women more frequently than men, with a gender ratio of 3:1 [1] . It has been suggested that sex hormones are the reason for the difference, based on the inductive role of female hormones in the onset of the disease and the protective role of androgens [25] . Women are affected by RA at an earlier age and have higher disease activity markers [28- 
joint DAS (DAS28) and HAQ] [68].
With advances in available therapies in RA, the aim of treatment is disease remission [9] . However, the ability to respond favourably to treatment and achieve remission varies widely between patients. Several authors have attempted to identify predictive response factors to biologic treatments, which could help physicians adopt a more personalized therapeutic approach (i.e. the optimal therapy for each individual patient). Over the last few years there has been growing interest in a possible role for sex in predicting remission in RA. The response rate to many RA therapies, including DMARDs and TNF blockers, is lower in women [1015] . As for the influence of gender on the response to rituximab (RTX), a monoclonal antibody directed against CD20, the data are very limited. Clinical trials on RTX provide no data on the influence of gender on response, but according to the British Society for Rheumatology Biologics Register (BSRBR), there appears to be a lower response to RTX in women [1620] .
The Autoimmunity and Rituximab (AIR) registry is a French national registry founded by the Club Rhumatismes et Inflammations (CRI) and the French Society of Rheumatology (SFR) that records efficacy and safety data on RA patients treated with RTX. Therefore, using patients enrolled in this large prospective observational cohort, we aimed to evaluate the efficacy of RTX in women vs men in routine clinical practice.
Materials and methods
The AIR registry is a French nationwide, multicentre, prospective cohort investigating the efficacy and safety of RTX in patients receiving their first treatment for RA or an autoimmune disease. Briefly, all French hospital-and community-based units (primarily in rheumatology and internal medicine) were invited to join the registry. Centres were informed that including patients in this observational registry would not interfere with their current practice or involve additional laboratory testing. The AIR receives financial support (an unrestricted educational grant) from Roche. However, Roche was not involved in the design, protocol, data collection or statistical analysis of this study. All the patients gave informed consent for participation and the ethical committees of all participating centres approved the AIR registry [21] . This ethical approval includes broad consent to perform clinical research on behalf of the registry that is related to the aims of the registry. As this project falls within these research aims, no additional ethical approval was required to perform this analysis on the anonymized patient data.
The registry includes data from eligible patients (adult patients receiving RTX for RA) from 82 centres. The baseline characteristics of the patients [age, gender, disease duration, swollen joint count (SJC), tender joint count (TJC), visual analogue scale (VAS) for patient's global assessment], clinical disease activity scores (DAS28) and biological parameters (anti-CCP, RF, ESR and CRP) were recorded at baseline and at the follow-ups (6, 12, 18 and 24 months). Study nurses were specifically trained in RTX treatment and the use of electronic case report forms (e-CRFs) by the study coordinators (J.-E.G. and X.M.). Study nurses visited each centre regularly to update the clinical and biological data for the patients included. Missing data were minimized by providing the physician in charge of the patient and the study nurses with summaries of the gaps in data for each patient in each centre.
The efficacy of RTX was assessed by the remission rate, defined as a DAS28-ESR <2.6 and the percentage of EULAR responses (good to moderate vs non-response) according to the EULAR criteria during the follow-ups (6, 12, 18 and 24 months) [22] .
Statistical analysis
Statistical analysis was performed using Stata, version 12 (StataCorp, College Station, TX, USA). The tests were two-sided, with a type I error set at a = 0.05 (except for multiple comparisons). Baseline characteristics are presented as the mean (S.D.) or median [interquartile range (IQR)] for each gender group for continuous data and as the number of patients and associated percentages for categorical parameters. Comparisons of these baseline characteristics between male and female patients were analysed using the chi-squared or Fisher's exact test for categorical variables and Student's t-test or MannWhitney test for quantitative variables, with normality verified by the ShapiroWilk test and homoscedasticity by the FisherSnedecor test. The relationship between the EULAR response or EULAR remission status (at 6, 12, 18 and 24 months) and gender was explored in multivariate analysis using a random effects model (generalized linear mixed model with logit link function), which made it possible to consider interaction between gender and time, subject random effect and adjustment on fixed effects (age, disease duration, RF or anti-CCP positivity, number of previous TNF blockers, corticoids use) and RA activity assessed by the DAS28-ESR and DAS28-CRP. To study differences between gender groups for variations in the DAS28-ESR and DAS28-CRP (differences with baseline), linear mixed models were used; residual normality was checked for these models. To assess the issue of missing data, the estimation methods developed by Verbeke and Molenberg [23] were considered in this study.
Results

Population characteristics
The characteristics of the population at baseline are presented in Table 1 At baseline there were no significant differences between men and women in terms of age (P = 0.15), number of previous anti-TNF agents (P = 0.15), presence of RF (P = 0.17), SJC (P = 0.43), TJC (P = 0.53) or VAS for www.rheumatology.oxfordjournals.org global assessment (P = 0.14), disease activity [DAS28-ESR (P = 0.6), DAS28-CRP (P = 1)] or ESR (P = 0.7). However, women had generally longer disease duration [13 years (IQR 820) vs 17 (1024), P < 0.001], fewer anti-CCP antibodies (74.4% vs 80.7%, P = 0.03) and lower CRP levels [28.5 mg/l (IQR 5.138) vs 32.6 (7.948), P < 0.001].
Efficacy of RTX
The response to RTX according to gender is shown in Table 2 . After adjustment (i.e. age, disease duration, RF or anti-CCP positivity, number of previous TNF blockers, corticoid use, RA activity assessed by the DAS28-ESR and DAS28-CRP), the remission rate did not significantly differ between men and women at 6 months (n = 812 patients, women 11% vs men 13%, P = 0.81). Twelve months after starting RTX, men appeared to have a better remission rate than women (n = 690, men 18% vs women 10.5%, P = 0.045). This difference was no longer significant at 18 (n = 608, women 13.7% vs men 19.4%, P = 0.35) or 24 months (n = 550, women 13.9% vs men 15.3%, P = 0.70).
In terms of EULAR response, no significant difference (good to moderate responders vs non-responders) was found between men and women at 6 (n = 757, P = 0.38), 12 (n = 642, P = 0.74), 18 (n = 566, P = 0.053) or 24 months (n = 506, P = 0.71). Regarding the components of the DAS28, the SJC, TJC and VAS for patient global assessment did not differ between men and women at any endpoints.
A supplementary analysis was performed on both subgroups: anti-TNF naive patients (n = 399) and patients who experienced anti-TNF failure (n = 1300) before receiving RTX. Six months after receiving RTX, remission was more frequently achieved by anti-TNF naive women vs men (women 25% vs men 7%, P < 0.01) and by men who experienced anti-TNF failure vs women (women 7% vs men 15%, P < 0.01). After 12 and 18 months, men more frequently achieved remission in cases of anti-TNF failure (women 10% vs men 17%, P = 0.02 and women 13% vs men 25%, P < 0.01, respectively). After 18 months, a better remission rate was obtained in anti-TNF naive women than men (women 19% vs men 3%, P = 0.02).
A total of 1178 patients (69%), including 1321 women and 387 men, experienced a second course of RTX with a mean delay of 12 months (S.D. 7.1) without difference in terms of gender [men 12.2 months (S.D. 7.9) vs women 11.9 months (S.D. 6.8), P = 0.26]. Eight hundred thirteen patients received a third course after a mean of 11.6 months (S.D. 5.9), without any differences in terms of gender.
Discussion
According to the French AIR registry, we found no significant differences in terms of EULAR response between men and women in patients treated with RTX for RA in the whole population. However, remission rates were higher in men than women after 12 months and there was a trend for a better EULAR good or moderate response in men after 18 months. Furthermore, we also found differences in remission rates according to previous anti-TNF exposure: remission rates were higher in men in the anti-TNF failure subgroup and in women in the anti-TNF naive subgroup.
In several studies, disease activity of RA measured by the DAS28 is higher in women than in men, in contrast to our results [6À8, 24À26]. Women also had higher TJC and apatient global assessment than men [24, 27] . This could 
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45 (54) 13 (59) be explained by a greater perception of pain [28] . In our study, none of the components of the DAS28, including TJC, SJC and patient global assessment, differed significantly between genders. Female gender has been suggested as a factor in poor RA prognosis, and response rates to RA treatment seem to be lower in women [10À15] . In an observational study including 142 RA patients treated by DMARDs, Mö ttö nen et al. [10] reported that men achieved remission more frequently than women with similar treatments in the two groups. The Swedish BARFOT cohort of 698 patients with early RA reported similar findings after 2 and 5 years of treatment (DMARD and/or biologics) [25, 26] . According to Jawaheer et al. [12] , a better response to anti-TNF agents was obtained in men with early RA than in women. Our results for RTX response between genders contrast with the previous findings of the BSRBR. For the BSRBR, lesser improvement in the DAS28 [coefficient 0.45 (95% CI 0.12, 0.78)] was observed in women than in men 6 months after RTX, but the analysis was limited to patients who experienced anti-TNF failure [20] . In our study, analysis of the two subgroups (anti-TNF naive patients and patients who failed anti-TNF therapy) shows similar results in cases of anti-TNF failure, with higher remission rates in men than in women at 6, 12 and 18 months. However, in the case of anti-TNF naive patients, our results showed that women seem to achieve remission more frequently than men. This comparison of response in anti-TNF naive patients is not available in the BSRBR. These differences could not be explained by discrepancies in the characteristics of the AIR registry population. In our study, women had longer disease duration and a lower CRP level at baseline than men. These results are similar to those previously reported by Arkema et al. [27] from the Swedish ARTIS registry. In addition, male patients often have more anti-CCP antibodies and higher levels of RF [29] . In our study, only anti-CCP antibodies, not RF, were more frequently observed in men.
The results of functional impairment and disability status as assessed by the HAQ were not available in the AIR registry because the HAQ is not collected in daily practice, but it has been reported that it is significantly higher in women than men with RA [24] . This could be explained by greater male muscle strength and also a possible overestimation of their functional ability [24] .
Unfortunately radiographs were not available in the AIR registry, and this is a limitation of this study. However, radiographic progression was similar between genders under anti-TNF therapy according to the Dutch DANBIO registry [7] . Results are similar for the BARFOT registry [24] . As it is an observational study reflecting routine clinical practice, missing data for some variables is another possible limitation of our analysis.
In this large daily practice cohort of RA patients, we found no significant differences in EULAR response to RTX between men and women during the 2 years of follow-up. However, remission rates were significantly higher in men than in women after 12 months.
Moreover, the effect of gender on remission rates after RTX was dependent on previous anti-TNF exposure.
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Rheumatology key messages
. The influence of gender on response to rituximab in RA has not been previously described. . We report a better RA remission rate in men in cases of anti-TNF failure.
